The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Immunotherapy combinations in pancreaticobiliary cancers
Kim Anna Reiss, MD, University of Pennsylvania, Philadelphia, PA, talks on immunotherapy combinations in pancreaticobiliary cancers, accounting for the potential for unique biology in certain patients, either relating to a DNA damage repair variant or a patient’s immunobiology. A study on the cessation of chemotherapy in exchange for a PARP inhibitor with anti-CTLA4 in patients who had achieved a durable response with chemotherapy revealed this patient population may be immunologically distinct, this bearing clinical implications. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
